Pain, Postoperative
Conditions
Keywords
postoperative pain, VATS, activities of daily living, quality of life
Brief summary
The objective of the PAIN-STOP trial is to assess the feasibility of a larger randomized controlled trial (RCT) evaluating NMDA antagonists and IV steroids, as compared to placebo, in decreasing the chances of clinically significant persistent post-surgical pain (PPSP) after video assisted thoracoscopic surgeries (VATS). This is a multi-centre randomized, controlled clinical trial with a 2 x 2 factorial design. The pilot phase of the trial will recruit 48 patients and follow them for 3 months. Patients will be randomized to one of four groups: 1) NMDA active + Steroid placebo; 2) Steroid active + NMDA placebo; 3) NMDA active + Steroid active; 4) NMDA placebo + Steroid placebo.
Detailed description
Persistent Post-Surgical Pain (PPSP) after Video Assisted Thoracic Surgery (VATS) lobectomy procedures is an important health problem for which there is no effective method of prevention. NMDA antagonists and steroids can modify pain signaling-sensitization pathways, and inflammatory-immune pathways, and hence can potentially prevent the development of PPSP. These agents have been safely used in thoracic surgeries to obtain many perioperative benefits, without increasing the harmful effects. Since these agents act by different biological mechanisms, it is appropriate to study their effects in a factorial design to increase the trial efficiency. Before conducting a large multicenter trial, we propose to establish the feasibility by carrying out this feasibility trial. The objective of the PAIN-STOP trial is to assess the feasibility of a larger randomized controlled trial (RCT) evaluating NMDA antagonists and IV steroids, as compared to placebo, in decreasing the chances of clinically significant persistent post-surgical pain (PPSP) after video assisted thoracoscopic surgeries (VATS). This is a multi-centre randomized, controlled clinical trial with a 2 x 2 factorial design. The pilot phase of the trial will recruit 48 patients and follow them for 3 months. Patients will be randomized to one of four groups: 1) NMDA active + Steroid placebo; 2) Steroid active + NMDA placebo; 3) NMDA active + Steroid active; 4) NMDA placebo + Steroid placebo. Follow-up visit will be conducted in hospital; day 8 and month 2 by a phone call; and in person follow-up visits at 30 days and 3 months post-randomization; for patients who cannot attend in person, a telephone follow up will be done.
Interventions
DRUGNMDA active
NMDA active group will involve ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID \[first week\]; 10 mg BID \[following three weeks\]).
DRUGSteroid active
Steroid active group will involve two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.
DRUGNMDA placebo
NMDA active group will involve normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (1 capsule BID \[first week\]; 1 capsule BID \[following three weeks\]).
DRUGSteroid placebo
Steroid placebo group will involve two doses of normal saline; one dose given prior to starting surgery and one dose given on the morning of second postoperative day.
Sponsors
Population Health Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Patients, health care providers, data collectors, outcome adjudicators, and Investigators (e.g., Steering Committee Members) will all be blind to treatment allocation.
Intervention model description
We will randomize patients in a 1:1:1:1 fashion to receive; 1) NMDA active + dexamethasone placebo, 2) dexamethasone active + NMDA placebo, 3) NMDA active + dexamethasone active, and 4) NMDA placebo + dexamethasone placebo.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 18-75 years of age, * Planned elective VATS pulmonary lobectomy, * Provide written informed consent to participate.
Exclusion criteria
* Current pain on the same side of the chest of moderate to severe intensity (\>3/10 in 0-10 numerical rating scale (NRS) - where 0=no pain, 10=maximum pain), * Known intracranial mass or cerebral aneurysm or raised intraocular pressure, * Severe renal impairment (creatinine clearance based GFR of \<30ml/min), * Allergies to one or more of the study medications, * Steroid treatment \> 10mg/day of Prednisolone or its equivalent for \> 3 weeks within the last 3 months, * History of schizophrenia or bipolar disorder, * History of drug addiction (prescription or non-prescription drug addiction diagnosed by a physician, excluding alcohol), * Current diagnosis of Cushing's syndrome, * Pregnancy, * Previous participation in the PAIN-STOP trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recruitment | 6 months | Ability to recruit 90% of eligible patients. |
| Follow-up | 9 months | Ability to obtain follow-up in \>90% of enrolled patients, at three months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Use of narcotic analgesic medication | 3 months | Use of narcotic analgesic medication \> 3 days/week beyond 4 weeks and up to 3 months after randomization. |
| Presence of NP | 3 months | Presence of NP as \> 3 out 7 items using DN4 scale, at measured at 3 months after randomization. |
| BPI score | 3 months | Difference in interference with activities of daily living measured using Brief Pain Inventory interference score, measured at 3 months after randomization. |
| Thoracic surgery specific activity limitations | 3 months | Difference in thoracic surgery specific activity limitations, measured at 3 months after randomization. |
| Change in global health status | 3 months | Change in global health status measured using global impression of change (GIC) scale at 3 months after randomization. |
| Difference in Quality of Life | 3 months | Difference in Quality of Life (QoL) using European Organization for Research and Treatment of Cancer (EORTC) QoL-30 at 3 months after randomization. |
| NRS - Incidence of PPSP | 3 months | Intensity of PPSP on a scale of 0-10, at 3 months after randomization \[0-10 numerical rating scale (NRS) - where 0=no pain, 10=maximum pain\]. |
| NRS - Incidence of PPSP with movement evoked | 3 months | Incidence of PPSP (in and/or around the surgical scar) at 3 months after randomization, as the presence of movement evoked pain \> 3/10 in 0-10 NRS. |
| Rate of change of postoperative pain intensity | 3 months | The rate of change of postoperative pain intensity measured over time (pain trajectory). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Incidence of new intubation and positive pressure ventilation | 3 months | Incidence of new intubation and positive pressure ventilation |
| Incidence of surgical site infection | 3 months | Incidence of surgical site infection |
| Incidence of myocardial infarction and injury | 3 months | Incidence of myocardial infarction and myocardial injury after noncardiac surgery (MINS) |
| Incidence of postoperative pneumonia | 3 months | Incidence of postoperative pneumonia |
| Incidence of prolonged air-leak | 3 months | Incidence of prolonged air-leak |
Countries
Canada, United States
Outcome results
None listed